Cure8 research brief
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
Researchers in multi-omics and IBD biomarkers; clinical investigators; clinicians interested in precision medicine for biologic therapy.
This study profiled six omic layers from tissue, fecal, and serum samples collected before and after anti-TNF therapy in 33 IBD patients, and compared trajectories to 20 non-IBD controls and an independent cohort of 38 non-responders who received alternative treatments.
The team developed an analytical framework that reduces dimensionality to extract biologically interpretable multi-omic response trajectories. The paper is a preprint and presents an analytical framework and comparative cohort data rather than a completed clinical implementation.
The findings suggest potential utility for personalized therapy selection but do not provide clinically validated biomarkers or direct treatment recommendations.
Preprint/abstract-level source: the work outlines an analytical framework and exploratory cohort comparisons but has not been peer reviewed or clinically validated; cohort sizes are modest.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
